Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs
This 2013 review discusses the pharmacology of serotonin (5-HT) receptors and highlights two selective 5-HT receptor subtype-targeted drugs: lorcaserin and pimavanserin. Lorcaserin is a 5-HT₂C receptor agonist approved for obesity treatment, promoting satiety through hypothalamic activation. Pimavanserin is a 5-HT₂A receptor inverse agonist approved for Parkinson’s disease psychosis, offering antipsychotic